<DOC>
	<DOCNO>NCT01844752</DOCNO>
	<brief_summary>This 12 week clinical trial subject acne vulgaris . Subjects randomize NVN1000 1 % Gel , NVN1000 4 % Gel Vehicle Gel twice daily . Safety , tolerability efficacy assess course study .</brief_summary>
	<brief_title>A Phase 2 , 3 Arm Study NVN1000 Gel Vehicle Gel Subjects With Acne</brief_title>
	<detailed_description>This multi-center , evaluator subject blind , randomize , vehicle-controlled , parallel group , dose-ranging study conduct approximately 150 subject acne vulgaris . Subjects satisfy entry criterion Baseline visit randomize NVN1000 1 % Gel , NVN1000 4 % Gel Vehicle Gel 1:1:1 ratio . Efficacy assessment include inflammatory non-inflammatory lesion count investigator global assessment ( IGA ) . Tolerability safety assessment include cutaneous tolerability evaluation , adverse event collection , physical exam , laboratory study . Subjects return post-baseline evaluation Weeks 2 , 4 , 8 , 12 .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Subjects acne vulgaris least 20 40 inflammatory lesion , 2570 noninflammatory lesion , 2 nodule face Baseline IGA score mild , moderate severe Women childbearing potential must agree use effective method birth control study 30 day final study visit Any dermatologic condition medical problem could interfere clinical evaluation require use topical systemic therapy make evaluation lesion count inconclusive Female subject pregnant , nursing , consider become pregnant Methemoglobin &gt; 2 % baseline Clinically significant anemia baseline Use topical systemic medication treat acne Use medication make acne bad , associate methemoglobinemia , nitric oxide donor</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>acne</keyword>
</DOC>